Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Nov 2, 2025 | (Q4)Nov 2, 2025 | (Q3)Aug 3, 2025 | (Q2)May 4, 2025 | (Q1)Feb 2, 2025 | (FY)Nov 3, 2024 | (Q4)Nov 3, 2024 | (Q3)Aug 4, 2024 | (Q2)May 5, 2024 | (Q1)Feb 4, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 23.87%63.89B | 28.18%18.02B | 22.03%15.95B | 20.16%15B | 24.71%14.92B | 43.99%51.57B | 51.20%14.05B | 47.27%13.07B | 42.99%12.49B | 11.96B |
| Operating revenue | 23.87%63.89B | 28.18%18.02B | 22.03%15.95B | 20.16%15B | 24.71%14.92B | 43.99%51.57B | 51.20%14.05B | 47.27%13.07B | 42.99%12.49B | --11.96B |
| Cost of revenue | 8.01%20.59B | 14.13%5.77B | 11.30%5.25B | 2.04%4.81B | 4.03%4.77B | 71.31%19.07B | 74.93%5.05B | 73.89%4.72B | 79.95%4.71B | 4.59B |
| Gross profit | 33.18%43.29B | 36.07%12.25B | 28.09%10.7B | 31.13%10.2B | 37.56%10.15B | 31.67%32.51B | 40.50%9B | 35.56%8.36B | 27.16%7.78B | 7.38B |
| Operating expense | -1.68%17.22B | 13.26%4.6B | 8.53%4.63B | -5.24%4.28B | -20.53%3.71B | 112.56%17.51B | 88.35%4.06B | 103.48%4.27B | 115.40%4.52B | 4.67B |
| Selling and administrative expenses | -15.08%4.21B | 9.60%1.11B | -2.55%1.07B | -15.19%1.08B | -39.63%949M | 211.49%4.96B | 141.63%1.01B | 183.51%1.1B | 191.55%1.28B | --1.57B |
| Research and development costs | 17.91%10.98B | 33.44%2.98B | 29.62%3.05B | 11.51%2.69B | -2.38%2.25B | 77.23%9.31B | 60.95%2.23B | 73.27%2.35B | 84.07%2.42B | --2.31B |
| Depreciation amortization depletion | -37.39%2.03B | -37.64%507M | -37.56%507M | -38.81%506M | -35.48%511M | 132.71%3.24B | 133.62%813M | 132.00%812M | 137.64%827M | --792M |
| -Depreciation and amortization | -37.39%2.03B | -37.64%507M | -37.56%507M | -38.81%506M | -35.48%511M | 132.71%3.24B | 133.62%813M | 132.00%812M | 137.64%827M | --792M |
| Operating profit | 73.88%26.08B | 54.78%7.65B | 48.47%6.07B | 81.61%5.92B | 137.96%6.43B | -8.84%15B | 16.27%4.95B | 0.57%4.09B | -18.92%3.26B | 2.7B |
| Net non-operating interest income (expenses) | 18.01%-2.86B | 9.01%-414M | 24.15%-807M | 26.55%-769M | 5.72%-873M | -221.25%-3.49B | -450.00%-455M | -162.07%-1.06B | -158.52%-1.05B | -926M |
| Non-operating interest income | -24.73%347M | ---- | ---- | ---- | ---- | -13.83%461M | ---- | ---- | ---- | ---- |
| Non-operating interest expense | -18.80%3.21B | -16.92%761M | -24.15%807M | -26.55%769M | -5.72%873M | 143.71%3.95B | 126.17%916M | 162.07%1.06B | 158.52%1.05B | --926M |
| Other net income (expenses) | 69.58%-483M | 48.97%-371M | 108.14%18M | 70.24%-61M | 84.14%-69M | -494.76%-1.59B | -74.76%-727M | -151.14%-221M | -297.12%-205M | -435M |
| Gain on sale of security | -41.67%-17M | ---- | ---- | ---- | ---- | -209.09%-12M | ---- | ---- | ---- | ---- |
| Special income (charges) | 61.45%-591M | 54.09%-146M | 38.28%-187M | 70.55%-86M | 72.26%-172M | -528.28%-1.53B | -2,346.15%-318M | -42.92%-303M | -3,144.44%-292M | ---620M |
| -Less:Restructuring and mergern&acquisition | -61.45%591M | -54.09%146M | -38.28%187M | -70.55%86M | -72.26%172M | 528.28%1.53B | 2,346.15%318M | 42.92%303M | 3,144.44%292M | --620M |
| Other non-operating income (expenses) | 390.70%125M | 47.61%-208M | 150.00%205M | -71.26%25M | -44.32%103M | -26.47%-43M | 4.11%-397M | -33.87%82M | -23.01%87M | --185M |
| Income before tax | 129.22%22.73B | 82.54%6.87B | 88.35%5.29B | 153.62%5.09B | 309.09%5.49B | -34.32%9.92B | -5.14%3.76B | -21.49%2.81B | -46.04%2.01B | 1.34B |
| Income tax | -110.59%-397M | -273.08%-1.65B | -72.98%1.15B | 203.45%120M | -119.12%-13M | 269.26%3.75B | -199.77%-442M | 1,463.84%4.24B | -149.36%-116M | 68M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 292.30%23.13B | 96.99%8.52B | 320.80%4.14B | 134.09%4.97B | 315.32%5.5B | -58.14%5.9B | 22.70%4.32B | -156.77%-1.88B | -39.07%2.12B | 1.33B |
| Net income continuous operations | 274.94%23.13B | 102.57%8.52B | 389.11%4.14B | 134.09%4.97B | 331.95%5.5B | -56.20%6.17B | 19.32%4.21B | -143.35%-1.43B | -39.07%2.12B | --1.27B |
| Net income discontinuous operations | --0 | --0 | --0 | --0 | --0 | ---273M | --119M | ---443M | --0 | --51M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 292.30%23.13B | 96.99%8.52B | 320.80%4.14B | 134.09%4.97B | 315.32%5.5B | -58.14%5.9B | 22.70%4.32B | -156.77%-1.88B | -39.07%2.12B | 1.33B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 292.30%23.13B | 96.99%8.52B | 320.80%4.14B | 134.09%4.97B | 315.32%5.5B | -58.14%5.9B | 22.70%4.32B | -156.77%-1.88B | -39.07%2.12B | 1.33B |
| Diluted earnings per share | 286.61%0.8668 | 95.65%0.3178 | 320.00%0.1554 | 128.26%0.1854 | 303.45%0.2066 | -62.54%0.2242 | 7.86%0.1624 | -150.00%-0.0706 | -45.17%0.0812 | 0.0512 |
| Basic earnings per share | 287.80%0.8421 | 93.33%0.3072 | 312.50%0.1501 | 134.09%0.1818 | 307.14%0.2013 | -62.73%0.2171 | 9.09%0.1589 | -151.95%-0.0706 | -46.01%0.0777 | 0.0494 |
| Dividend per share | 6.37%0.066 | 7.75%0.0167 | 9.87%0.0168 | 4.10%0.0162 | 3.87%0.0163 | 351.45%0.062 | 12.53%0.0155 | 0.0153 | 0.0156 | 0.0157 |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.